Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04356287
Other study ID # MP-05-2020-2251
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 5, 2023
Est. completion date December 2025

Study information

Verified date April 2024
Source Sir Mortimer B. Davis - Jewish General Hospital
Contact Marie Hudson, MD
Phone 514-340-8222
Email marie.hudson@mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UCMSC) for the treatment of Systemic Sclerosis (SSc).


Description:

A single-center, three-arm, randomized, double-blind, placebo-controlled trial is proposed. A total of 18 SSc patients will be enrolled in 3 successive blocks of 6 patients each. After being informed about the study and potential risks, all patients giving written informed consent will be randomized to one of two treatment arms or a placebo arm (total of 6 patients per arm). Within each block, the 6 patients will be randomized in a 2:2:2 ratio in one of the following arms: placebo, 1 infusion of UCMSC (M0), or 2 infusions of UCMSC (M0, M3). Second infusions of UCMSC will be performed only in the absence of Treatment Related Severe Adverse Events (TRSAE). Randomization into blocks 2 and 3 will be staggered, to allow the detection of TRSAE prior to inclusion of patients in a subsequent block, i.e. the second block will be randomized only in the absence of TRSAE one month after the first infusion of all 6 patients in block one, and similarly for the third block.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. SSc according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2103 classification criteria for systemic sclerosis 2. Severe disease defined as: i) disease duration of 2 years or less with an mRss of > 20 and (ESR > 25 mm and/or hemoglobin < 11 g/dL, not explained by other causes than SSc), or ii) mRss >15 without any restriction as to disease duration plus at least one major organ involvement as defined by: a) respiratory involvement consisting of lung diffusion capacity for carbon monoxide (DLCO) and/or forced vital capacity (FVC) < 80% predicted and evidence of interstitial lung disease (chest X-ray and/or high resolution computed tomography (HRCT) scan); b) renal involvement consisting of past renal crisis and/or stage 2 or 3 chronic kidney disease (glomerular filtration rate between 30-89 mL/min) not explained by other causes than SSc; c) cardiac involvement consisting of reversible congestive heart failure, atrial or ventricular rhythm disturbances such as recurrent episodes of atrial fibrillation or flutter, recurrent atrial paroxysmal tachycardia, conduction abnormalities (2nd or 3rd degree atrioventricular block), and/or mild to moderate pericardial effusion. All causes of organ involvement should be attributed to SSc. 3. Inadequate response (determined by patient and physician judgement) or adverse events necessitating discontinuation of standard therapy (usually consisting of methotrexate 25 mg subcutaneous (or as tolerated) per week and/or mycophenolate mofetil 2-3 gm/d (or as tolerated) for at least 3 months 4. Ineligibility or unwillingness to undergo autologous hematopoietic stem cell transplant Exclusion Criteria: 1. Age < 18 years 2. Pregnancy or unwillingness to use adequate contraception 3. Life-threatening end-organ damage defined as: - FVC < 45% and/or DLCO (corrected for hemoglobin) < 30% predicted; - Left ventricular ejection fraction < 40% by cardiac echocardiography; - Pulmonary hypertension with baseline resting systolic pulmonary arterial pressures > 50 mmHg by cardiac echocardiography, or mean pulmonary artery pressure > 25 mmHg (and pulmonary wedge pressure < 15 mmHg) on right heart catheterization; - stage 4 or more chronic kidney disease (glomerular filtration rate < 30 ml/min) 4. Liver failure defined as an abnormal transaminase level (aspartate aminotransferase (ASAT), alanine aminotransaminase (ALAT) > 3 normal) unless related to activity of the disease 5. Concurrent neoplasms or myelodysplasia 6. Uncontrolled hypertension 7. Uncontrolled acute or chronic infection (HIV, HTLV-1/2 (Human T-lymphotropic virus), hepatitis B surface Ag positive, hepatitis C positive) or high risk thereof 8. Significant malnutrition with BMI < 18 kg/m2 9. Severe concomitant psychiatric disorder 10. Bone marrow insufficiency defined as neutropenia < 0.5 x 109 cell/L, thrombocytopenia < 30 x 109 cell/L, anemia < 8g/dL, CD4+ T lymphopenia < 200 x 106 cell/L due to other diseases than SSc (CD4 - cluster of differentiation 4) 11. History of poor compliance 12. Concurrent enrolment in any other protocol using an investigational drug 13. Inability to provide informed consent

Study Design


Intervention

Biological:
UCMSC
Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
Other:
Placebo
Each infusion will consist of 50 mL of PlasmaLyte A.

Locations

Country Name City State
Canada Sir Mortimer B. Davis Jewish General Hospital Montreal Quebec

Sponsors (7)

Lead Sponsor Collaborator
Marie Hudson, MD Assistance Publique - Hôpitaux de Paris, Centre hospitalier de l'Université de Montréal (CHUM), McGill University Health Centre/Research Institute of the McGill University Health Centre, Medical University of South Carolina, Université de Montréal, University Paris 7 - Denis Diderot

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Liang J, Zhang H, Kong W, Deng W, Wang D, Feng X, Zhao C, Hua B, Wang H, Sun L. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018 Nov 14;9(1):312. doi: 10.1186/s13287-018-1053-4. — View Citation

Wang D, Zhang H, Liang J, Wang H, Hua B, Feng X, Gilkeson GS, Farge D, Shi S, Sun L. A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. Stem Cell Reports. 2018 Mar 13;10(3):933-941. doi: 10.1016/j.stemcr.2018.01.029. Epub 2018 Mar 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Safety at the time of infusion, 24 hours, 10 days +/- 24 hours, Month 6, Month 9 and Month 12 (adverse events) Measure of safety of UCMSC in severe SSc using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification [https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm] 24 hours, 10 days +/- 24 hours, Month 6, Month 9 and Month 12
Other Mortality occurring after randomization and up to study completion Causes of death and their relation to SSc versus the study intervention will be evaluated by the Data and Safety Monitoring Committee (DSMC). 1 year
Other Modified Rodnan skin score A measure of skin thickness [Khanna et al., 2017] Month 0, Month 3, Month 6 and Month 9
Other World Health Organization (WHO) performance status WHO performance status [Oken et al., 1982] describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). Month 0, Month 3, Month 6, Month 9 and Month 12
Other Scleroderma-Health Assessment Questionnaire Disease status as measured by the Scleroderma-Health Assessment Questionnaire [Steen & Medsger, 1997] Month 0, Month 3, Month 6, Month 9 and Month 12
Other 36-Item Short Form Survey version 2 for health-related quality of life (SF-36v2) Health-related quality of life as measured by the SF-36v2 [Ware et al., 2007] Month 0, Month 3, Month 6, Month 9 and Month 12
Other EuroQoL health status measure (EQ-5D-5L) Health related quality of life in cost effectiveness analysis as measured by the EQ-5D-5L [Herdman et al., 2011] using five levels of severity in five dimensions. Month 0, Month 3, Month 6, Month 9 and Month 12
Other Response to treatment Defined as decrease in mRss > 25%, increase in FVC > 10% predicted (forced vital capacity) and/or increase in DLCO >15% predicted (diffusing capacity of the lungs for carbon monoxide), without need for further immunosuppression except low dose steroids Month 0, Month 12
Other Progression-free survival Progression defined as any one of the following: decrease in FVC > 10% predicted; decrease in DLCO > 15% predicted; decrease in left ventricular ejection fraction on cardiac echocardiography > 15%; decrease in weight > 15%; decrease in creatinine clearance > 30%; increase in mRss > 25%; and/or increase in Scleroderma-Health Assessment Questionnaire > 0.5 Month 0, Month 12
Other Global Rank Composite Score A composite score consisting of a hierarchy of ordered outcomes: death, event-free survival (survival without respiratory, renal, or cardiac failure), FVC, score on the Disability Index of the Health Assessment Questionnaire (HAQ-DI; range, 0 to 3, with higher scores indicating more disability), and the modified Rodnan skin score. [Sullivan et al., 2018] Month 0, Month 12
Other ACR Provisional Composite Response Index ACR Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (CRISS) [Khanna et al., 2016], a composite measure of treatment response in SSc Month 0, Month 12
Primary Measure of safety one month after first infusion Treatment related severe adverse event using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification [https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm] Month 1
Secondary Change in modified Rodnan skin score (mRss) between Month 0 and Month 12 A measure of skin thickness; difference between Month 12 and Month 0 on the mRss [Khanna et al., 2017] Month 0 and Month 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01219465 - Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus Phase 1/Phase 2
Active, not recruiting NCT01221428 - Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis Phase 1/Phase 2
Completed NCT03105284 - Adipose-tissue Derived Stem Cells in Flaps Versus Liposuction N/A
Not yet recruiting NCT01224327 - Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients Phase 1/Phase 2
Recruiting NCT06149832 - Treatment of Oral Chronic Graft-versus-host Disease With Human Umbilical Cord Mesenchymal Stem Cell Dressing Phase 4
Recruiting NCT05165459 - Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers N/A
Active, not recruiting NCT04014166 - Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia N/A
Not yet recruiting NCT06077734 - Muscle Stem Cell Quality in Atrophy
Completed NCT00956891 - Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation Phase 1/Phase 2
Recruiting NCT01218464 - Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure Phase 1/Phase 2
Active, not recruiting NCT03874572 - Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth Phase 1
Recruiting NCT00953485 - Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) Phase 1/Phase 2
Not yet recruiting NCT04863183 - Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis Phase 1/Phase 2
Completed NCT06360861 - Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1
Completed NCT05018754 - Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF
Completed NCT03130374 - Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells Phase 1/Phase 2
Active, not recruiting NCT02673788 - Follow-Up Study of Safety of Pneumostem® in Premature Infants With Intraventricular Hemorrhage
Recruiting NCT01763099 - Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Phase 2
Recruiting NCT01763086 - Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant Phase 2
Completed NCT02302599 - Mesenchymal Stem Cells to Treat Type 2 Diabetes Phase 2